Literature DB >> 28425656

Considering the esophagogastric junction as a 'zone'.

Shin Ichihara1, Noriya Uedo2, Takuji Gotoda3.   

Abstract

Siewert's classification of adenocarcinoma of the esophagogastric junction (EGJ) classifies tumors anatomically for determining the appropriate surgical technique. According to this classification, a type II tumor, true carcinoma of the cardia, is defined as a cancer within 1 cm proximal to 2 cm distal of the EGJ. Histological analysis indicates that the cardiac gland is present with a high degree of frequency between 1-2 cm to the gastric side and 1-2 cm to the esophageal side of the EGJ, which means that this zone can be considered as neither the stomach nor the esophagus but rather as a third zone known as the 'EGJ zone'. It has been suggested that there are multiple causes for development of adenocarcinoma in the EGJ zone. The TNM Classification of Malignant Tumours 7th Edition considers EGJ adenocarcinoma (EGJAC) occurring in the EGJ zone to be a part of esophageal adenocarcinoma (EAC). However, recent studies have indicated that EGJAC behaves differently from EAC and gastric carcinoma. Barrett's esophagus is now considered an important factor in the etiology of EGJAC, but, as yet, no studies have elucidated the differences between cancer arising from short-segment Barrett's esophagus and cancer of the gastric cardia. Thus, there is currently no clinical relevance to subdivision of adenocarcinoma in the EGJ zone into above or below the EGJ line.
© 2017 The Authors. Digestive Endoscopy © 2017 Japan Gastroenterological Endoscopy Society.

Entities:  

Keywords:  adenocarcinoma; barrett's esophagus; esophageal neoplasm; esophagogastric junction; gastric neoplasm

Mesh:

Year:  2017        PMID: 28425656     DOI: 10.1111/den.12792

Source DB:  PubMed          Journal:  Dig Endosc        ISSN: 0915-5635            Impact factor:   7.559


  5 in total

1.  Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Esophageal/Gastric Cardia Adenocarcinoma Among Men.

Authors:  Jessica L Petrick; Paula L Hyland; Patrick Caron; Roni T Falk; Ruth M Pfeiffer; Sanford M Dawsey; Christian C Abnet; Philip R Taylor; Stephanie J Weinstein; Demetrius Albanes; Neal D Freedman; Susan M Gapstur; Gary Bradwin; Chantal Guillemette; Peter T Campbell; Michael B Cook
Journal:  J Natl Cancer Inst       Date:  2019-01-01       Impact factor: 13.506

2.  Potential Value of Radiomics in the Identification of Stage T3 and T4a Esophagogastric Junction Adenocarcinoma Based on Contrast-Enhanced CT Images.

Authors:  Xu Chang; Xing Guo; Xiaole Li; Xiaowei Han; Xiaoxiao Li; Xiaoyan Liu; Jialiang Ren
Journal:  Front Oncol       Date:  2021-03-03       Impact factor: 6.244

3.  Endoscopic Versus Surgical Therapy for Early Esophagogastric Junction Adenocarcinoma Based on Lymph Node Metastasis Risk: A Population-Based Analysis.

Authors:  Hua Ye; Ping Chen; Yi-Fan Wang; Xiu-Jun Cai
Journal:  Front Oncol       Date:  2021-12-17       Impact factor: 6.244

4.  SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma.

Authors:  Li-Ying OuYang; Zi-Jian Deng; Yu-Feng You; Jia-Ming Fang; Xi-Jie Chen; Jun-Jie Liu; Xian-Zhe Li; Lei Lian; Shi Chen
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

5.  Prognostic Nomogram for Postoperative Patients With Gastroesophageal Junction Cancer of No Distant Metastasis.

Authors:  Qiang Guo; YuanYuan Peng; Heng Yang; JiaLong Guo
Journal:  Front Oncol       Date:  2021-04-16       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.